What are the recommended pharmacologic treatments for restless leg syndrome?

Restless Leg Syndrome Medication

For adults with restless legs syndrome, start with gabapentin enacarbil, gabapentin, or pregabalin as first-line therapy, and correct iron deficiency with IV ferric carboxymaltose when ferritin is low—dopamine agonists should be avoided as standard treatment due to high risk of augmentation. 1

First-Line Pharmacologic Treatments

The 2025 American Academy of Sleep Medicine guidelines represent a major paradigm shift away from dopaminergic therapy. The evidence now strongly supports α2δ calcium channel ligands as the cornerstone of RLS treatment 1, 2:

Strong Recommendations (Use These First):

• Gabapentin enacarbil (strong recommendation, moderate certainty)
• Gabapentin (strong recommendation, moderate certainty)
• Pregabalin (strong recommendation, moderate certainty)
• IV ferric carboxymaltose for patients with low iron stores (strong recommendation, moderate certainty)

These medications improve sleep architecture, reduce wakefulness, and carry minimal risk of augmentation—the treatment-limiting complication that has plagued dopaminergic therapy 3, 4.

Iron Repletion is Critical

Check iron parameters in all RLS patients. The guideline recommends IV iron therapy when iron stores are suboptimal (specific thresholds provided in good practice statements) 1. This addresses a core pathophysiological mechanism rather than just symptom suppression 3.

Additional iron options with conditional recommendations include:

• Oral ferrous sulfate (conditional, moderate certainty) 1
• IV low molecular weight iron dextran (conditional, very low certainty) 1
• IV ferumoxytol (conditional, very low certainty) 1

Important caveat: Ferric carboxymaltose can cause hypophosphatemia more than other IV iron formulations—monitor phosphate levels 2.

Second-Line and Alternative Options

When α2δ ligands are insufficient or not tolerated:

Conditional Recommendations:

• Extended-release oxycodone and other opioids (conditional, moderate certainty) 1

  • The National RLS Opioid Registry shows reassuring safety data 2
  • Reserve for refractory cases or when first-line options fail
  • Monitor for respiratory depression and addiction risk

• Dipyridamole (conditional, low certainty) 1

  • Note: Not supported by World Sleep Society due to limited global availability 5

• Bilateral high-frequency peroneal nerve stimulation (conditional, moderate certainty) 1

  • Emerging device-based therapy for refractory cases 2

What NOT to Use

Dopamine Agonists—The Critical Change

The AASM now suggests AGAINST standard use of all dopamine agonists due to augmentation risk with long-term use 1:

• Pramipexole (suggest against, moderate certainty)
• Ropinirole (suggest against, moderate certainty)
• Transdermal rotigotine (suggest against, low certainty)
• Levodopa (suggest against, very low certainty)

These may only be considered for short-term use in patients who prioritize immediate symptom relief over long-term safety 1. This represents a complete reversal from historical practice where dopamine agonists dominated treatment 3.

Strong Recommendation Against:

• Cabergoline (strong recommendation against, moderate certainty) 1

Other Medications to Avoid:

• Bupropion (suggest against, moderate certainty) 1
• Carbamazepine (suggest against, low certainty) 1
• Clonazepam (suggest against, very low certainty) 1
• Valproic acid (suggest against, low certainty) 1
• Valerian (suggest against, very low certainty) 1

Special Populations

End-Stage Renal Disease (ESRD):

• Gabapentin (conditional, very low certainty) 1
• IV iron sucrose when ferritin <200 ng/mL and transferrin saturation <20% (conditional, moderate certainty) 1
• Vitamin C (conditional, low certainty) 1

Children:

• Ferrous sulfate when iron stores are appropriate (conditional, very low certainty) 1
• Limited pharmacologic data in pediatrics—iron repletion is key 6

Clinical Algorithm

1. Assess iron status first in all patients—treat deficiency with IV ferric carboxymaltose or oral ferrous sulfate
2. Start α2δ ligand (gabapentin enacarbil, gabapentin, or pregabalin) for moderate-to-severe symptoms
3. If inadequate response, consider adding or switching to opioids (extended-release oxycodone)
4. Avoid dopamine agonists unless patient explicitly prioritizes short-term relief and accepts augmentation risk
5. For refractory cases, consider combination therapy or peroneal nerve stimulation

Common Pitfalls

• Don't start dopamine agonists first—the augmentation risk (worsening symptoms, earlier onset, spread to other body parts) makes them unsuitable for chronic management 7, 3
• Don't overlook iron deficiency—even without anemia, low ferritin drives RLS pathophysiology 3
• Don't use intermittent dosing for chronic symptoms—daily persistent RLS requires daily treatment 6
• Don't continue medications that worsen RLS—antidepressants, antihistamines, and dopamine antagonists exacerbate symptoms 8

The modern approach is "augmentation-aware, iron-conscious, and phenotype-oriented" 3, prioritizing sustainable long-term management over short-term symptom suppression.